Outcome | Group | Baseline | 3-month follow-up | 6-month follow-up | 12-month follow-up | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |  | Mean | SD | N | Mean | SD | N | Mean | SD | N | Mean | SD | N |
HBI | Group 1 | 3.30 | 3.2 | 10 | 5.50 | 6.05 | 8 | 11.20 | 5.45 | 5 | 8.00 | 2.45 | 5 |
Group 2 | 4.33 | 2.74 | 9 | 5.50 | 4.46 | 6 | 7.80 | 3.70 | 5 | 5.00 | 0.00 | 3 | |
SCCAI | Group 1 | 5.22 | 3.22 | 3 | 4.00 | 2.83 | 2 | 7 | 0 | 1 | 11.00 | 4.24 | 2 |
Group 2 | 4.50 | 2.52 | 4 | 4.50 | 1.22 | 6 | 8.67 | 1.16 | 3 | 7.50 | 0.71 | 2 | |
IBD-F1 | Group 1 | 11.93 | 3.24 | 14 | 8.00 | 4.61 | 9 | 7.83 | 3.66 | 6 | 8.43 | 2.51 | 7 |
Group 2 | 9.93 | 4.13 | 15 | 9.45 | 4.97 | 11 | 8.13 | 4.16 | 8 | 8.00 | 2.65 | 5 | |
IBD-F2 | Group 1 | 55.83 | 26.74 | 12 | 23.40 | 15.09 | 10 | 31.75 | 25.86 | 6 | 29.85 | 18.89 | 7 |
Group 2 | 49.00 | 28.66 | 15 | 44.20 | 30.96 | 10 | 23.49 | 25.33 | 8 | 21.05 | 12.66 | 5 | |
IBDQ | Group 1 | 89.67 | 13.67 | 15 | 97.50 | 11.20 | 10 | 91.83 | 18.70 | 6 | 97.57 | 8.89 | 7 |
Group 2 | 93.79 | 8.87 | 14 | 95.27 | 10.10 | 11 | 100.88 | 10.86 | 8 | 100.00 | 4.30 | 5 | |
BIPQ | Group 1 | 41.13 | 6.20 | 15 | 32.40 | 6.83 | 10 | Â | Â | Â | Â | Â | Â |
Group 2 | 42.40 | 7.14 | 15 | 43.20 | 6.14 | 10 | Â | Â | Â | Â | Â | Â | |
ESS | Group 1 | 13.87 | 4.85 | 15 | 7.00 | 4.42 | 10 | Â | Â | Â | Â | Â | Â |
Group 2 | 10.19 | 4.69 | 16 | 9.82 | 3.90 | 11 | Â | Â | Â | Â | Â | Â | |
GAD7 | Group 1 | 9.80 | 5.54 | 15 | 4.50 | 3.53 | 10 | Â | Â | Â | Â | Â | Â |
Group 2 | 8.00 | 5.27 | 16 | 5.00 | 3.52 | 11 | Â | Â | Â | Â | Â | Â | |
PHQ9 | Group 1 | 12.00 | 6.01 | 15 | 6.00 | 4.42 | 10 | Â | Â | Â | Â | Â | Â |
Group 2 | 9.75 | 6.00 | 16 | 8.73 | 4.71 | 11 | Â | Â | Â | Â | Â | Â |